- November 2013
Highlights of the European Cancer Congress - cancer society presidents give their view.
- October 2013
Richard Schilsky on the changes needed as personalised medicine enters the clinic.
- September 2013
A new advance in immunotherapy is discussed by Jean-Charles Soria and Caroline Robert.
- July/August 2013
EORTC President Roger Stupp on challenges for clinical trials research.
- June 2013
A look ahead to the European Cancer Congress in Amsterdam in September.
- May 2013
Vincenzo Valentini explores the themes of the 2013 ESTRO forum.
- April 2013
Discussing cancer in an ageing population.
- March 2013
Richard Sullivan on global issues in childhood cancer.
- February 2013
How to write a paper that will be cited 12,000 times.
- January 2013
What predictions do oncologists have for the coming year?
EJC News Focus – September 2013
EJC's Drug of the Year, 2013
Immunotherapy is finally emerged from the shadows as a realistic – and perhaps essential – tool in cancer control. After decades of painstaking research which yielded little benefit for patients, immunotherapy has entered a fresh phase with the development of new agents that can either activate the immune system or re-awaken silenced immune responses to a tumour.
The emerging paradigm, by which only the most effective immune cells are selectively harnessed to target the tumour, is an immediate advance for patients. It also holds the promise of future steps forward, as clinicians and researchers learn how best to use the new agents in combination.
In this month's EJC News Focus, Jean-Charles Soria and Caroline Robert, both from Institut Gustave Roussy, Paris-Sud, France, explain to Helen Saul why the Programmed Death-1 receptor (PD-1), and its ligand (PD-L1), have been recognised in EJC's Drug of the Year article, 2013.